Physitrack Limited

As of June 30, 2026, Physitrack Limited carries a market capitalization of 125.53M, placing it among publicly traded companies globally. Its enterprise value stands at 168.42M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Physitrack Limited's next confirmed earnings release is scheduled for February 26, 2027.

As of June 30, 2026, Physitrack Limited has 16.26M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.84, and the price-to-book ratio stands at 1.15.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 168.42M versus a market cap of 125.53M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Physitrack Limited maintains a current ratio of 0.45, meaning it holds 0.5x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 43.22, indicating elevated leverage, while an interest coverage ratio of -4.04 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Physitrack Limited posted a negative return on equity (ROE) of -58.99, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -35.96, reflecting losses generated across the asset base.

Over the twelve months ended June 30, 2026, Physitrack Limited recorded 990,966.87 in income tax expense. The company reported a pretax loss of -66.58M and -92.11M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Physitrack Limited's stock has declined approximately 18.21% over the past 52 weeks. The 50-day moving average sits at 9.23, while the 200-day moving average is 9.09.

Over the twelve months ended June 30, 2026, Physitrack Limited generated 148.77M in revenue and converted that into -92.11M in net income, yielding earnings per share of -4.16. EBITDA reached -18.64M, while operating income came in at 6.69M.

As of June 30, 2026, Physitrack Limited holds 4.40M in cash and equivalents against 47.29M in total debt, resulting in a net debt position of 42.89M. Total book value stands at 109.40M, with working capital of -24.83M providing operational flexibility.

Physitrack Limited produced 42.89M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -34.98M in capital expenditures, free cash flow totaled 7.91M - equivalent to 0.49 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of 4.50 and net profit margin of -61.92 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 6.30, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 3.28, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Physitrack Limited shareholders.

As of June 30, 2026, Physitrack Limited has an Altman Z-Score of -2.78, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.